Cannabis Use May Worsen Seizure Frequency in Epilepsy Patients

A newly reported study finds that epilepsy patients who use cannabis may face an increase in seizure frequency, a result that cuts against the widespread assumption that cannabis is broadly protective against seizures.

The finding matters for clinical practice because a substantial share of epilepsy patients already use cannabis products, often without telling their neurologist. For clinicians reading routine scalp EEG in epilepsy monitoring units and outpatient labs, the message is direct: cannabis use belongs in the medication and lifestyle history taken at every visit, because it may be a modifiable driver of seizure worsening rather than an incidental detail.

What did the study find?

According to the report, epilepsy patients who used cannabis experienced more seizures rather than fewer. The finding stands in tension with the public narrative that has built up around cannabidiol (CBD) since the FDA cleared a purified CBD product for certain epilepsy syndromes. That regulatory clearance applies to a specific, standardized pharmaceutical formulation, not to whole-plant cannabis or dispensary products with variable cannabinoid content.

The distinction is critical for patient counseling. Cannabis contains many active compounds. Tetrahydrocannabinol (THC), the primary psychoactive component, and CBD can have divergent effects on neuronal excitability, and the ratio between them varies enormously across commercially available products. A study finding seizure worsening with general cannabis use does not contradict the evidence base for purified CBD in specific syndromes, but it does complicate the picture for patients who interpret headlines about CBD as license to self-medicate with unregulated products.

Why does this matter for neurologists and EEG labs?

For epileptologists, seizure worsening in a previously controlled patient typically triggers a review of adherence, sleep, stressors, and medication changes. This finding suggests cannabis use deserves a place on that checklist. Patients frequently underreport cannabis use, whether because of legal concerns or because they assume it is irrelevant to their neurological care.

Clinical neurophysiology teams should also consider the implications for monitoring. Interictal and ictal findings on scalp EEG, and intracranial recordings where applicable, reflect the patient's overall excitability state, including pharmacological influences. A patient whose seizure frequency rises after starting cannabis presents a diagnostic puzzle that clinicians can only solve if they know about the exposure.

The finding also raises questions about cannabinoid effects on cortical excitability that EEG research is well positioned to answer. Quantitative EEG studies of acute and chronic cannabis exposure have documented changes in cortical rhythms, and epilepsy-specific investigations could help clarify whether particular cannabinoids or product types drive the apparent seizure worsening.

How should clinicians respond?

Several practical steps follow from the reported finding:

• Ask epilepsy patients about cannabis use explicitly at each visit, including product type, THC/CBD content when known, and frequency.
• Document cannabis exposure in the record alongside antiseizure medications, since it may confound interpretation of seizure trends and EEG findings.
• Counsel patients that a seizure increase coinciding with cannabis initiation warrants discontinuation and reevaluation.
• Distinguish clearly, in patient conversations, between FDA-cleared purified CBD formulations and non-standardized cannabis products.

What comes next?

The study underscores the need for larger, prospective investigations that stratify patients by product composition, cannabinoid ratios, epilepsy syndrome, and concomitant antiseizure medications. Until such data exist, the reported association between cannabis use and increased seizures gives neurologists a concrete reason to screen, document, and counsel, rather than assume that patient-reported cannabis use is seizure-neutral.